Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?

The bench trial in Teva Pharmaceutical USA Inc.'s Copaxone (glatiramer) patent infringement suit against Mylan Pharmaceuticals Inc. and Sandoz Inc. concluded on Sept. 21 and the parties now await a decision by the judge. If Teva is successful, it may end up asking itself what a victory in this patent battle would cost in the broader war on biosimilars.